Previous 10 | Next 10 |
Supports Clinical and Commercial Supply Needs for Multiple Batten Disease Programs Advances Amicus Mission to Deliver Novel Gene Therapies to Rare Disease Patients CRANBURY, N.J., July 01, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (NASD...
Jill Weimer, PhD named Senior Vice President of Discovery Research and Gene Therapy Science Simon Jordan named Senior Vice President of International CRANBURY, N.J., June 13, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced two new additions to the Sen...
Amicus Therapeutics ( FOLD ) is best known for its Fabry disease drug Galafold, which has already been approved by the FDA. However, in 2018, it made a huge change when it generated an agreement with the University of Pennsylvania to generate gene therapy treatments for a host of rare diseases...
CRANBURY, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total of 18,720,930 shares of its common stock, including 2,441,860 shares of common stock sold pursuan...
CRANBURY, N.J., June 03, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following scientific and investor conferences in June. Upcoming Scientific Conference: Michael C. Diem, MD, Senior Vice President of Business and Corporat...
Amicus Therapeutics ( FOLD ) has priced its public offering of 16.28M common shares at $10.75 per share, for gross proceeds of $175M, More news on: Amicus Therapeutics, Inc., Read more ...
CRANBURY, N.J., May 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the pricing of an underwritten offering of 16,279,070 shares of its common stock at $10.75 per share. The gross proceeds from the offering to Amicus are expected to be $175 million, before de...
Gainers: Obalon Therapeutics (NASDAQ: OBLN ) +42% . Eltek (NASDAQ: ELTK ) +35% . SilverSun Technologies (NASDAQ: SSNT ) +33% . MiMedx Group ( OTC:MDXG ) +31% . BioCryst Pharmaceuticals (NASDAQ: BCRX ) +19% . Tocagen (NASDAQ: TOCA ) +17% . Hydrogenics Corporation (NASDAQ: HYGS )...
Gainers: ECOR +26.2% . KEYS +7.7% . VEEV +6.3% . IAG +1.9% . VRNT +1.8% . More news on: electroCore, Inc., Keysight Technologies, Inc., Veeva Systems Inc., Stocks on the move, Read more ...
CRANBURY, N.J., May 29, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced a $150 million underwritten public offering of its common stock. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint book-ru...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K....